| Identification | Back Directory | [Name]
SB 209670 | [CAS]
157659-79-5 | [Synonyms]
SB 209670
SB209670,SB 209670
SB209670, CID108002
(1S,2R,3S)-1-(1,3-BENZODIOXOL-5-YL)-3-[2-(CARBOXYMETHYLOXY)-4-METHOXYPHENYL]-5-PROPOXY-2,3-DIHYDRO-1H-INDENE-2-CARBOXYLIC ACID
1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-[2-(carboxymethoxy)-4-methoxyphenyl]-2,3-dihydro-5-propoxy-, (1S,2R,3S)- | [Molecular Formula]
C29H28O9 | [MOL File]
157659-79-5.mol | [Molecular Weight]
520.53 |
| Hazard Information | Back Directory | [Uses]
SB-209670 is an extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist. SB 209670 selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki=0.2 and 18 nM, respectively). SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty[1]. | [References]
[1] E H Ohlstein, et al. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8052-6. DOI:10.1073/pnas.91.17.8052 |
|
|